Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.4%

1 terminated/withdrawn out of 29 trials

Success Rate

96.2%

+9.6% vs industry average

Late-Stage Pipeline

14%

4 trials in Phase 3/4

Results Transparency

44%

11 of 25 completed trials have results

Key Signals

2 recruiting11 with results

Enrollment Performance

Analytics

N/A

13(61.9%)

Phase 3

4(19.0%)

Phase 2

2(9.5%)

Phase 1

2(9.5%)

21Total

N/A(13)

Phase 3(4)

Phase 2(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT05386030Phase 3Completed

Saypha® VOLUME Lidocaine for Midface Augmentation

Role: lead

NCT07492277Recruiting

A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines

Role: lead

NCT07398755Completed

Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure

Role: collaborator

NCT07475455Active Not Recruiting

Filler Post Market Survey (FIPS)

Role: lead

NCT07398768Recruiting

Prospective, Non-interventional Study Assessing Perioral Rejuvenation Procedure

Role: collaborator

NCT07374965Completed

A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A

Role: collaborator

NCT03985982Phase 3Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

Role: lead

NCT03050710Not ApplicableCompleted

Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds

Role: lead

NCT04883632Not ApplicableCompleted

Saypha® Volume LIdocaine in Nasolabial Folds

Role: lead

NCT02677298Phase 3Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

Role: lead

NCT02677805Phase 3Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

Role: lead

NCT03611491Not ApplicableCompleted

Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds

Role: lead

NCT04763265Phase 2Completed

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Role: lead

NCT04917588Not ApplicableCompleted

Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmentation

Role: lead

NCT01798498Not ApplicableCompleted

Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds

Role: lead

NCT03990883Not ApplicableCompleted

Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF)

Role: lead

NCT06135337Not ApplicableCompleted

THIODERM ELATE for Augmentation of Very Thin, Thin, and Moderately Thick Lips

Role: lead

NCT06128109Not ApplicableCompleted

THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume Deficit

Role: lead

NCT06133153Not ApplicableWithdrawn

THIODERM ELATE for Volume Augmentation in Lips

Role: lead

NCT03923634Not ApplicableCompleted

Princess® RICH for the Correction of Fine Lines

Role: lead